Serum levels of sclerostin as a potential biomarker in central arterial stiffness among hypertensive patients

Serum levels of sclerostin as a potential biomarker in central arterial stiffness among hypertensive patients is a paper indexed in ScholarIQ from OpenAlex.

How many citations does Serum levels of sclerostin as a potential biomarker in central arterial stiffness among hypertensive patients have?

Serum levels of sclerostin as a potential biomarker in central arterial stiffness among hypertensive patients has 17 citations in the OpenAlex counts ScholarIQ stores.

When was Serum levels of sclerostin as a potential biomarker in central arterial stiffness among hypertensive patients published?

Serum levels of sclerostin as a potential biomarker in central arterial stiffness among hypertensive patients has 2018 year in the ScholarIQ index.

What is the open-access status of Serum levels of sclerostin as a potential biomarker in central arterial stiffness among hypertensive patients?

Serum levels of sclerostin as a potential biomarker in central arterial stiffness among hypertensive patients has gold oa status in the ScholarIQ index.

What is the DOI of Serum levels of sclerostin as a potential biomarker in central arterial stiffness among hypertensive patients?

The DOI for Serum levels of sclerostin as a potential biomarker in central arterial stiffness among hypertensive patients is on the source record.

What is the PMID of Serum levels of sclerostin as a potential biomarker in central arterial stiffness among hypertensive patients?

The PMID for Serum levels of sclerostin as a potential biomarker in central arterial stiffness among hypertensive patients is on the source record.

What is the OpenAlex record for Serum levels of sclerostin as a potential biomarker in central arterial stiffness among hypertensive patients?

The OpenAlex for Serum levels of sclerostin as a potential biomarker in central arterial stiffness among hypertensive patients is on the source record.